The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka biosciences; Exelixis; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
 
Yu-Hui Chen
Employment - Ribonaut Therapeutics (I); Ribonaut Therapeutics (I)
 
David Jarrard
No Relationships to Disclose
 
Jorge Garcia
Honoraria - Aptitude Health; Astellas Pharma; MJH Associates; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Macrogenics; Pfizer; Targeted Oncology
Research Funding - Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Premier, Inc. (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Novartis; Pfizer
Other Relationship - FDA
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AVEO; Bayer; Gilead Sciences; Janssen Oncology; Macrogenics; Merck; Pfizer
Research Funding - Arvinas (Inst); Exelixis (Inst); Seagen (Inst)
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Janssen medical Affairs
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
 
Maha Hussain
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Bayer
 
Daniel Shevrin
Consulting or Advisory Role - Astellas Pharma
 
Matthew Cooney
Employment - Parexel International; Tempus
Leadership - Tempus AI, Inc.
 
Mario Eisenberger
No Relationships to Disclose
 
Manish Kohli
Employment - nference (I)
Stock and Other Ownership Interests - Atzeyo Biosensors; Cancer Healing Networks
Honoraria - Advanced Accelerator Applications
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Cytogen; Genapsys; Tempus
Patents, Royalties, Other Intellectual Property - Patent number: 10982286. Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
Travel, Accommodations, Expenses - Celgene; Olink Proteomics INC
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Nicholas Vogelzang
No Relationships to Disclose
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Michael Carducci
Honoraria - Remedica
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)
 
Robert DiPaola
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination